Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881762 · ClinicalTrials.gov registry record · Phase 4
Maraviroc Efficacy for Hepatitis C
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02881762 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants.
The verdict
NCT02881762, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking antiretroviral therapy for HIV.
Interventions
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2019-03-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02881762
The ClinicalTrials.gov registry entry for NCT02881762 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maraviroc is the first listed.
NCT02881762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02881762 about?
NCT02881762 is a clinical study titled "Maraviroc Efficacy for Hepatitis C". This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking antiretroviral therapy for HIV.
What is the current status of trial NCT02881762?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-06-01. Estimated completion is 2019-03-27.
What interventions are being tested in trial NCT02881762?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02881762?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.